ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för varespladib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

28 träffar

Bibliografisk träff 2022-01-12

Action of Varespladib (LY-315920), a Phospholipase A2 Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of Lachesis muta rhombeata (South-American Bushmaster) Venom.

Gutierres PG, Pereira DR, Vieira NL, Arantes LF, Silva NJ, Torres-Bonilla KA, Hyslop S, Morais-Zani K, Nogueira RMB, Rowan EG, Floriano RS.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2021.812295

Bibliografisk träff 2021-12-18

Varespladib (LY315920) rescued mice from fatal neurotoxicity caused by venoms of five major Asiatic kraits (Bungarus spp.) in an experimental envenoming and rescue model.

Tan CH, Lingam TMC, Tan KY.

Acta Trop · journal article · DOI 10.1016/j.actatropica.2021.106289

Bibliografisk träff 2021-11-10

In vivo treatment with varespladib, a phospholipase A2 inhibitor, prevents the peripheral neurotoxicity and systemic disorders induced by Micrurus corallinus (coral snake) venom in rats.

Silva-Carvalho R, Gaspar MZ, Quadros LHB, Lobo LGG, Rogério LM, Santos NTS, Zerbinatti MC, Santarém CL, Silva EO, Gerez JR, Silva NJ, Lomonte B, Rowan EG, Floriano RS.

Toxicol Lett · journal article · DOI 10.1016/j.toxlet.2021.11.003

Bibliografisk träff 2021-10-21

Role of Phospholipases A2 in Vascular Relaxation and Sympatholytic Effects of Five Australian Brown Snake, Pseudonaja spp., Venoms in Rat Isolated Tissues.

Vuong NT, Jackson TNW, Wright CE.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2021.754304

Bibliografisk träff 2021-09-22

Varespladib (LY315920) prevents neuromuscular blockage and myotoxicity induced by crotoxin on mouse neuromuscular preparations.

Maciel FV, Ramos Pinto ÊK, Valério Souza NM, Gonçalves de Abreu TA, Ortolani PL, Fortes-Dias CL, Garrido Cavalcante WL.

Toxicon · journal article · DOI 10.1016/j.toxicon.2021.09.009

Bibliografisk träff 2021-07-15

The design and discovery of phospholipase A2 inhibitors for the treatment of inflammatory diseases.

Batsika CS, Gerogiannopoulou AD, Mantzourani C, Vasilakaki S, Kokotos G.

Expert Opin Drug Discov · review; journal article · DOI 10.1080/17460441.2021.1942835

Bibliografisk träff 2021-04-23

Anticoagulant Activity of Naja nigricollis Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib.

Kazandjian TD, Arrahman A, Still KBM, Somsen GW, Vonk FJ, Casewell NR, Wilkinson MC, Kool J.

Toxins (Basel) · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/toxins13050302

Bibliografisk träff 2021-04-16

The synthetic varespladib molecule is a multi-functional inhibitor for PLA2 and PLA2-like ophidic toxins.

Salvador GHM, Borges RJ, Lomonte B, Lewin MR, Fontes MRM.

Biochim Biophys Acta Gen Subj · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbagen.2021.129913

Bibliografisk träff 2020-12-25

Snake venom proteome of Protobothrops mucrosquamatus in Taiwan: Delaying venom-induced lethality in a rodent model by inhibition of phospholipase A2 activity with varespladib.

Liu CC, Wu CJ, Hsiao YC, Yang YH, Liu KL, Huang GJ, Hsieh CH, Chen CK, Liaw GW.

J Proteomics · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jprot.2020.104084

Bibliografisk träff 2020-09-02

Varespladib (LY315920) inhibits neuromuscular blockade induced by Oxyuranus scutellatus venom in a nerve-muscle preparation.

Fontana Oliveira IC, Gutiérrez JM, Lewin MR, Oshima-Franco Y.

Toxicon · journal article · DOI 10.1016/j.toxicon.2020.08.023

Bibliografisk träff 2020-06-17

Varespladib Inhibits the Phospholipase A2 and Coagulopathic Activities of Venom Components from Hemotoxic Snakes.

Xie C, Albulescu LO, Still KBM, Slagboom J, Zhao Y, Jiang Z, Somsen GW, Vonk FJ, Casewell NR, Kool J.

Biomedicines · research-article; journal article · DOI 10.3390/biomedicines8060165

Bibliografisk träff 2020-06-05

Varespladib (LY315920) neutralises phospholipase A2 mediated prothrombinase-inhibition induced by Bitis snake venoms.

Youngman NJ, Walker A, Naude A, Coster K, Sundman E, Fry BG.

Comp Biochem Physiol C Toxicol Pharmacol · journal article · DOI 10.1016/j.cbpc.2020.108818

Bibliografisk träff 2020-05-29

PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky's Viper Vipera berus nikolskii.

Zinenko O, Tovstukha I, Korniyenko Y.

Toxins (Basel) · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/toxins12060356

Bibliografisk träff 2020-05-19

Anticoagulant activity of black snake (Elapidae: Pseudechis) venoms: Mechanisms, potency, and antivenom efficacy.

Zdenek CN, Youngman NJ, Hay C, Dobson J, Dunstan N, Allen L, Milanovic L, Fry BG.

Toxicol Lett · journal article · DOI 10.1016/j.toxlet.2020.05.014

Bibliografisk träff 2020-02-20

Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms.

Gutiérrez JM, Lewin MR, Williams DJ, Lomonte B.

Toxins (Basel) · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/toxins12020131

Bibliografisk träff 2019-11-20

Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920).

Salvador GHM, Gomes AAS, Bryan-Quirós W, Fernández J, Lewin MR, Gutiérrez JM, Lomonte B, Fontes MRM.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-019-53755-5

Bibliografisk träff 2018-12-04

Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib).

Bittenbinder MA, Zdenek CN, Op den Brouw B, Youngman NJ, Dobson JS, Naude A, Vonk FJ, Fry BG.

Toxins (Basel) · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/toxins10120516

Bibliografisk träff 2018-11-17

Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and Rescue Juvenile Pigs from Lethal Doses of Micrurus fulvius (Eastern Coral Snake) Venom.

Lewin MR, Gilliam LL, Gilliam J, Samuel SP, Bulfone TC, Bickler PE, Gutiérrez JM.

Toxins (Basel) · research-article; journal article · DOI 10.3390/toxins10110479

Bibliografisk träff 2018-11-14

Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A2.

Bryan-Quirós W, Fernández J, Gutiérrez JM, Lewin MR, Lomonte B.

Toxicon · journal article · DOI 10.1016/j.toxicon.2018.11.292

Bibliografisk träff 2018-02-12

Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation.

Wang Y, Zhang J, Zhang D, Xiao H, Xiong S, Huang C.

Molecules · research-article; journal article · DOI 10.3390/molecules23020391

Bibliografisk träff 2016-08-25

Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.

Lewin M, Samuel S, Merkel J, Bickler P.

Toxins (Basel) · research-article; journal article · DOI 10.3390/toxins8090248

Bibliografisk träff 2012-10-11

Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS.

De Luca D, Minucci A, Piastra M, Cogo PE, Vendittelli F, Marzano L, Gentile L, Giardina B, Conti G, Capoluongo ED.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0047066

Bibliografisk träff 2011-01-01

Varespladib.

Författaruppgift saknas

Am J Cardiovasc Drugs · review; journal article · DOI 10.2165/11533650-000000000-00000

Bibliografisk träff 2010-10-01

Varespladib methyl in cardiovascular disease.

Rosenson RS, Fraser H, Trias J, Hislop C.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2010.517193

Bibliografisk träff 2005-08-01

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis.

Zeiher BG, Steingrub J, Laterre PF, Dmitrienko A, Fukiishi Y, Abraham E, EZZI Study Group.

Crit Care Med · clinical trial; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/01.ccm.0000171540.54520.69

Bibliografisk träff 2004-10-02

Effect of a selective inhibitor of secretory phospholipase A2, S-5920/LY315920Na, on experimental acute pancreatitis in rats.

Tomita Y, Kuwabara K, Furue S, Tanaka K, Yamada K, Ueno M, Ono T, Maruyama T, Ajiki T, Onoyama H, Yamamoto M, Hori Y.

J Pharmacol Sci · comparative study; journal article · DOI 10.1254/jphs.fp0040314

Bibliografisk träff 2003-03-01

Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.

Abraham E, Naum C, Bandi V, Gervich D, Lowry SF, Wunderink R, Schein RM, Macias W, Skerjanec S, Dmitrienko A, Farid N, Forgue ST, Jiang F.

Crit Care Med · comparative study; clinical trial; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/01.ccm.0000053648.42884.89

Bibliografisk träff 1999-03-01

Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI.

Snyder DW, Bach NJ, Dillard RD, Draheim SE, Carlson DG, Fox N, Roehm NW, Armstrong CT, Chang CH, Hartley LW, Johnson LM, Roman CR, Smith AC, Song M, Fleisch JH.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1016/s0022-3565(24)38064-4

Gå till forskningen.

Publikationer i urvalet

Action of Varespladib (LY-315920), a Phospholipase A<sub>2</sub> Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of <i>Lachesis muta rhombeata</i> (South-American Bushmaster) Venom.

Varespladib (LY315920) rescued mice from fatal neurotoxicity caused by venoms of five major Asiatic kraits (Bungarus spp.) in an experimental envenoming and rescue model.

In vivo treatment with varespladib, a phospholipase A<sub>2</sub> inhibitor, prevents the peripheral neurotoxicity and systemic disorders induced by Micrurus corallinus (coral snake) venom in rats.

Role of Phospholipases A<sub>2</sub> in Vascular Relaxation and Sympatholytic Effects of Five Australian Brown Snake, <i>Pseudonaja</i> spp., Venoms in Rat Isolated Tissues.

Varespladib (LY315920) prevents neuromuscular blockage and myotoxicity induced by crotoxin on mouse neuromuscular preparations.

The design and discovery of phospholipase A<sub>2</sub> inhibitors for the treatment of inflammatory diseases.

Anticoagulant Activity of <i>Naja nigricollis</i> Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib.

The synthetic varespladib molecule is a multi-functional inhibitor for PLA<sub>2</sub> and PLA<sub>2</sub>-like ophidic toxins.

Snake venom proteome of Protobothrops mucrosquamatus in Taiwan: Delaying venom-induced lethality in a rodent model by inhibition of phospholipase A<sub>2</sub> activity with varespladib.

Varespladib (LY315920) inhibits neuromuscular blockade induced by Oxyuranus scutellatus venom in a nerve-muscle preparation.

Varespladib Inhibits the Phospholipase A<sub>2</sub> and Coagulopathic Activities of Venom Components from Hemotoxic Snakes.

Varespladib (LY315920) neutralises phospholipase A<sub>2</sub> mediated prothrombinase-inhibition induced by Bitis snake venoms.

PLA<sub>2</sub> Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky's Viper <i>Vipera berus nikolskii</i>.

Anticoagulant activity of black snake (Elapidae: Pseudechis) venoms: Mechanisms, potency, and antivenom efficacy.

Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms.

Structural basis for phospholipase A<sub>2</sub>-like toxin inhibition by the synthetic compound Varespladib (LY315920).

Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib).

Delayed LY333013 (Oral) and LY315920 (Intravenous) Reverse Severe Neurotoxicity and Rescue Juvenile Pigs from Lethal Doses of <i>Micrurus fulvius</i> (Eastern Coral Snake) Venom.

Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A<sub>2</sub>.

Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation.

Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.

Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS.

Varespladib.

Varespladib methyl in cardiovascular disease.

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis.

Effect of a selective inhibitor of secretory phospholipase A2, S-5920/LY315920Na, on experimental acute pancreatitis in rats.

Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.

Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI.